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Group B meningitis remains a major world health problem and the poor
immunogenicity (1) of the group B meningococcal polysaccharide (GBMP) pre-
vents the formulation of a comprehensive polysaccharide vaccine against me-
ningococcal meningitis (2, 3). Recently, a highly immunogenic form of the GBMP
was made by conjugating a chemically modified GBMP to tetanus toxoid (TT)
(4) . In this modification, N-propionyl (N-Pr) groups were substituted for the N-
acetyl groups of the GBMP . The antibodies induced in mice by the N-Pr-GBMP-
TT conjugate were bactericidal for GBM organisms, and on this evidence it
must be considered as a potential vaccine . However, it has been inferred that
such a vaccine could only be successful at the risk of breaking tolerance, and this
hypothesis is legitimized by the identification of a-2--+8-linked oligomers of sialic
acid common to both the GBMP (5, 6) and to human and animal tissue (7, 8) .
Therefore, it was important to identify the epitopeon theN-Pr-GBMP-conjugate
associated with the production of bactericidal antibody . The conjugate induced
in mice two distinct populations ofN-Pr-GBMP-specific antibodies, associated
with two different epitopes, one which is shared by the GBMP. However, of
particular interest to the above problem is the fact that bactericidal activity was
associated with an epitope on the N-Pr-GBMP not present on the exogenous
GBMP .
Materials and Methods
BriefDefinitive Report
Materials . The strains (groups and protein serotypes in parenthesis) of Neisseria
meningitidis disease isolates used in this study were M986 (B:2a:P1 .2), 2996 (B:2b:P1 .2),
80278 (B:2b:P1 .2), 83101 (B:2b:P1 .2), 85066 (B:2b:P1 .2), 44/76 (B:15:P1 .16), 85095
(B:nontypable), 81014 (C:2a:P1 .2), 85088 (W135:nontypable), and 85079 (A) . The high
molecular weight GBMP was provided by Dr . W . Hankins, Connaught Laboratories,
Swiftwater, PA . The N-propionylation of the GBMP and the subsequent synthesis of the
N-Pr-GBMP-TT conjugate have been previously described (4) . Antisera were obtained
from two different groups of female CFI mice after threefold intraperitoneal injections
with the N-Pr-GBMP-TT conjugate in CFA (4), and the antisera were pooled (pools 1
and 2) and heat inactivated at 56 °C for 30 min .
Bactericidal Assays.
￿
A modification of a microbactericidal assay (9) was used . Twofold
dilutions of the serum were made in Dulbecco's PBS, pH 7.2, containing magnesium and
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TABLE I
Bactericidal Activity ofPool 1 ofMouse Anti-N-Pr-GBMP-TT
Conjugate Serum againstMeningococcal Disease Isolates
Strain (serogroup/serotype)
￿
Bactericidal titer
M986 (B:2a:P1 .2)
￿
4,096
2996 (B:26:PL2)
￿
2,048
80278 (B:26:P1 .2)
￿
4,096
83101 (B:2b:P1.2)
￿
2,048
85066 (B:2b:P1 .2)
￿
1,024
44/76 (B:15:P1 .16)
￿
4,096
85095 (Bmontypable)
￿
4,096
81014 (C:2a:P1 .2)
￿
<4
85088 (W135:nontypable)
￿
<4
85079 (A)
￿
<4
calcium (10) and 0.1% gelatin (DPBG) so that 50 Il of serum dilution were present in
each well of a sterile tissue culture multiwell plate (Linbro Chemical Co., Hamden, CT).
20-ttl of pooled undiluted baby rabbit serum was added to each well as a source of
complement. Controls included 50 ,1 DPBG and 20,ul of complement, 70 ',l of DPBG,
and 50 ul of serum dilution plus 20 141 of DPBG to ensure that activity was not due to
agglutination of the organisms. Meningococcal strains used in the assay were grown on
gonococcal (GC) medium (11) at 36° C in an atmosphere of 5% C02 for 4-5 h. The
organisms were diluted in DPBG and 30 A.1 of suspension containing ^-100 CFUs were
added to each well . The tissue culture plates were incubated at 36°C for 30 min after
which time 50 Al were removed from each well and spread on GC medium. The plates
were incubated at 36° C in an atmosphere of 5% C02 for 24 h and the number ofcolonies
were counted. The highest serum dilution (expressed as the reciprocal) causing a ?90%
reduction in viable count was considered the bactericidal titer of the serum. The results
were reproducible within one serum dilution.
Quantitative Microprecipitin Analyses.
￿
Analyses were performed in duplicate essentially
by the method of Kabat and Mayer (12). 20-,ul aliquots of pool 1 antiserum were diluted
with 80 1l of physiological-buffered saline (PBS, 0.01 M) at pH 7.2 and were reacted with
increasing concentrations of polysaccharides in a total volume of 200 '1 (adjusted with
PBS). The tubes were incubated for 1 h at 37'C and for 3 d at VC, C, centrifuged, washed,
and the quantity of protein in the pellet was determined by the method of Lowry et al.
(13). For absorption experiments the pooled serum (300 Al) was incubated with 30 ,ug of
N-Pr-GBMP or 1501Ag of GBMP (equilibrium quantities) in 1501,1 of PBS for 1 h at 37°C
followed by 4 d at 4°C. The precipitates were removed by centrifugation and the removal
of essentially all GBMP-specific antibodies from the GBMP-absorbed serum was monitored
by RIA using sH-labeled GBMP (6). Precipitin experiments on the absorbed serum were
carried out as described above using PBS to adjust to the dilution used previously. All the
above experiments were repeated on another preparation of mouse anti-N-Pr-GBMP-TT
conjugate serum (pool 2).
Results and Discussion
Because the N-Pr-GBMP-TT conjugate can induce high titers of GBMP-
specific IgG antibodies in mice (4), it must be considered as a vaccine against
meningitis caused by group B N. meningitidis . Additional evidence that supports
its candidacy is that antibodies raised in mice by the N-Pr-GBMP-TT conjugate
are highly bactericidal for group B meningococcal organisms. Experiments to
confirm this are shown in Table I and indicate that the pooled mouse antiserum
is bactericidal for a number of group B meningococcal disease strains isolated in
diverse geographical areas. The specificity of this bactericidal activity is demon-
strated by the inability of the pooled mouse antiserum to exhibit any significant25
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TABLE II
Bactericidal Activity ofNonabsorbed and Absorbed Pooled Mouse
Anti-N-Pr-GBMP-TT Conjugate Sera
1209
FIGURE 1 . Quantitative micro-
precipitin curves of mouse anti-
N-Pr-GBMP-TT conjugate serum
(pool 1) with N-Pr-GBMP (0) and
GBMP (EI). Also, the same serum
was absorbed with the GBMP be-
fore precipitation with N-Pr-
GBMP (A) and GBMP (9) .
bactericidal activity against N . meningitidis groups A, C, and W-135 organisms .
These experiments also demonstrate that the bactericidal activity of the mouse
N-Pr-GBMP-TT conjugate antiserum is completely independent of protein ser-
otype, and on this evidence it seems reasonable to assume that the bactericidal
activity is due to crossreactive GBMP-specific antibodies . However, this was not
substantiated in subsequent experiments .
The presence oftwo distinct populations of antibodies in the pooled mouse N-
Pr-GBMP-TT conjugate antiserum was demonstrated in thequantitative precip-
itin experimentsshown in Fig . 1 . While thehomologous N-Pr-GBMPprecipitated
^-1 .25 mg/ml of antibody from the antiserum, the heterologous GBMP was also
able to precipitateapproximately halfthis amount . Furthermore, afterabsorption
of the antisera with the GBMP the N-Pr-GBMP was still able to precipitate
substantial amounts of the antibody . These experiments confirm that the N-Pr-
GBMP-TT conjugate antiserum contains two populations ofN-Pr-GBMP specific
antibodies, based on two different epitopes, only one of which is crossreactive
with the GBMP .
Using the above absorbed antisera it was also possible to determine which of
the above epitopes was responsible for the induction of bactericidal antibodies
in the mice (Table 11) . Absorption of two different batches of pooled mouse N-
Pr-GBMP-TT antisera with the N-Pr-GBMP removed virtually all of the bacte-
ricidal activity against group B meningococcal organisms in each case, whereas,
unexpectedly, neither antiserum lost its bactericidal activity (within the limits of
experimental error) when absorbed with the GBMP . To avoid any ambiguities
Absorbing antigen
Bactericidal
Pool I
Titer
Pool 2
None 2,048 512
GBMP 1,024 512
N-Pr-GBMP <16 <41210
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in this data as a result ofthe possibility ofsubstantial quantities ofGBMP-specific
antibodies remaining in the antisera after absorption with the GBMP, the
absorbed antisera were subjected to RIA (6) using a 'H-labeled GBMP. No
significant binding of the labeled GBMP to the absorbed antisera was detected.
Clearly, the antibodies that were bactericidal for group B meningococcal orga-
nisms did not bind to the GBMP.
This result has extremely important implications in that there has been much
discussion about the advisability of inducing GBMP-specific IgG antibodies in
humans even ifan immunogen to accomplish this was available. The objection is
based primarily on the hypothesis that the poor immunogenicity ofthe GBMP is
a natural self-protective phenomenon and is based on an epitope (a decasaccha-
ride of a-(2--+8)-linked sialic acid) common to the GBMP (6) and human and
animal tissue components (7, 8). This structural homology has been unambigu-
ously demonstrated in the case of glycopeptides isolated from human and rat
fetal brain tissue (7, 8), and the ability of these components to bind in vitro to
GBMP-specific antibodies has been established (14, 15). Whether this objection
is valid remains conjectural, and until there is conclusive evidence that this
approach is detrimental, attempts to make an immunogenic form of the GBMP
should not be abandoned. In the meantime we have demonstrated that although
the N-Pr-GBMP-TT conjugatedoes raise crossreactive GBMP-specific antibodies
in mice it also induces in them N-Pr-GBMP-specific antibodies that do not bind
to the GBMP but that are specifically bactericidal for group B N. meningitidis.
In conclusion, it can be inferred from the above evidence that the N-Pr-GBMP
mimics a unique bactericidal epitope on the surface of group B meningococcal
organisms that is not presenton exogenous GBMP. However, given thestructural
similarity between the N-Pr-GBMP and the GBMP it is likely that the GBMP,
probably in a modified form on the bacterial surface, is still involved in the
formation of the bactericidal epitope. Work is now in progress to define this
potentially important epitope.
Summary
Antibodies induced in mice by the N-propionyl (N-Pr)-group B meningococcal
polysaccharide (GBMP)-tetanus toxoid (TT) conjugate were bactericidal for
GBM organisms independent of protein serotype. The antisera contained two
populations of N-Pr-GBMP-specific antibodies, only one of which crossreacted
with the GBMP. Particularly significant was the fact that the bactericidal activity
was mainly associated with the population of antibodies that did not crossreact
with the GBMP. Therefore it can be inferred from the above evidence that the
N-Pr-GBMP mimics a unique epitope on the surface of GBM organisms that is
not present on the exogenous GBMP.
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